Novartis is planning to launch a COPD app it began developing two years ago to 10 countries this year. Interestingly enough, the company won’t make the app available in the US, at least not in the near future.
Formerly known as Helio, the application will be known as Volari COPD, and includes education, monitoring tools and gamification components to keep patients engaged. It won’t be a companion app for Novartis medications and it’s not designed to accompany specific medical devices.
According to the company’s spokeswoman, the app is looking to improve the patient-physician dialogue. “The patient-physician dialogue is sub-optimal and the compliance rate is very low (approximately 40 percent), leading to lack of engagement in managing their disease,” she said.
The results from the Volari COPD pilot of 160 patients in Netherlands, Spain and Brazil has shown promising results, increasing patient engagement by a margin: one-third of the participants checked in 25 consecutive days, and 70% said it gave them new health insights.
Volari COPD joins Novartis’ existing app portfolio which counts more than 100 titles.